Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists

Neuroendocrine neoplasms (NEN) are a variegated family of malignancies originating from the diffuse neuroendocrine system. They are mainly distinguished into “well differentiated” (WD) and “poorly differentiated” (PD) and are commonly named neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), respectively. This derives from the gastroenteropancreatic (GEP) WHO classification terminology that categorized these neoplasms in WD NET grade s 1, 2 and 3 or PD NEC [1]. Specifically, a Ki-67>20% defines the high-grade category, including NET G3 and NEC [2].

Source: Cancer Treatment Reviews - April 17, 2023 Category: Cancer & Oncology Authors: La Salvia A., Modica R., Rossi R.E., Spada F., Rinzivillo M., Panzuto F., Faggiano A., Cinieri S., Fazio N. Tags: Anti-tumour Treatment Source Type: research